• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗保健行业的财务绩效:全球、区域和行业特定的实证研究。

The financial performance of the health care industry: a global, regional and industry specific empirical investigation.

机构信息

Department of Finance, University of Regensburg, 93040, Regensburg, Germany.

出版信息

Eur J Health Econ. 2018 May;19(4):585-594. doi: 10.1007/s10198-017-0904-8. Epub 2017 Jun 2.

DOI:10.1007/s10198-017-0904-8
PMID:28577230
Abstract

This article analyzes the financial (out-) performance of all listed health care companies. The health care sector outperformed the market in the period from 2000 to June 2015. The performance was driven by companies from Americas, and Asia as well as companies from the pharmaceuticals sub-segment. Additionally, bull periods appear to be the main driver for the outperformance. Euro-based investors can expect different outcomes of their investments to those of USD investors. However, the main trends remain unchanged.

摘要

本文分析了所有上市医疗保健公司的财务(表现)绩效。在 2000 年至 2015 年 6 月期间,医疗保健行业的表现优于市场。这一表现的驱动力来自于来自美洲、亚洲以及制药子行业的公司。此外,牛市似乎是表现优异的主要驱动因素。基于欧元的投资者对其投资的预期结果可能与基于美元的投资者不同。然而,主要趋势保持不变。

相似文献

1
The financial performance of the health care industry: a global, regional and industry specific empirical investigation.医疗保健行业的财务绩效:全球、区域和行业特定的实证研究。
Eur J Health Econ. 2018 May;19(4):585-594. doi: 10.1007/s10198-017-0904-8. Epub 2017 Jun 2.
2
Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.组织工程/再生医学产品商业化中的障碍:政府资助机构和金融行业的试点调查。
Tissue Eng Part A. 2012 Nov;18(21-22):2187-94. doi: 10.1089/ten.TEA.2012.0186. Epub 2012 Sep 27.
3
Direct interaction in digital interactive media and stock performance: Evidence from Panorama.数字互动媒体中的直接互动与股票绩效:全景网的证据。
PLoS One. 2024 May 28;19(5):e0302448. doi: 10.1371/journal.pone.0302448. eCollection 2024.
4
The link between workforce health and safety and the health of the bottom line: tracking market performance of companies that nurture a "culture of health".劳动力健康与安全与底线健康之间的联系:跟踪培养“健康文化”的公司的市场绩效。
J Occup Environ Med. 2013 Sep;55(9):993-1000. doi: 10.1097/JOM.0b013e3182a6bb75.
5
The impact of sustainability performance indicators on financial stability: evidence from the Russian oil and gas industry.可持续性绩效指标对财务稳定性的影响:来自俄罗斯石油和天然气行业的证据。
Environ Sci Pollut Res Int. 2019 Mar;26(8):8157-8168. doi: 10.1007/s11356-019-04325-9. Epub 2019 Jan 28.
6
Wall Street's assessment of plastic surgery--related technology: a clinical and financial analysis.华尔街对整形手术相关技术的评估:一项临床与财务分析。
Plast Reconstr Surg. 2000 Feb;105(2):609-16. doi: 10.1097/00006534-200002000-00020.
7
Economic and non-economic determinants of Iranian pharmaceutical companies' financial performance: an empirical study.伊朗制药公司财务绩效的经济和非经济决定因素:一项实证研究。
BMC Health Serv Res. 2019 Dec 30;19(1):1011. doi: 10.1186/s12913-019-4735-4.
8
Public option and private profits: what do markets expect?公共选择与私人利润:市场预期如何?
Appl Health Econ Health Policy. 2010;8(3):155-65. doi: 10.2165/11535510-000000000-00000.
9
Trends in biopharmaceutical IPOS: 1996-2005.生物制药行业首次公开募股趋势:1996 - 2005年
J Health Care Finance. 2006 Winter;33(2):39-54.
10
Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies.ESGC 指标对上市制药公司财务绩效的影响。
Int J Environ Res Public Health. 2021 Apr 25;18(9):4556. doi: 10.3390/ijerph18094556.

本文引用的文献

1
Innovation in the pharmaceutical industry: New estimates of R&D costs.制药行业的创新:研发成本的新估计
J Health Econ. 2016 May;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. Epub 2016 Feb 12.
2
How the effects of aging and stresses of life are integrated in mortality rates: insights for genetic studies of human health and longevity.衰老效应与生活压力如何体现在死亡率中:对人类健康和长寿基因研究的启示
Biogerontology. 2016 Feb;17(1):89-107. doi: 10.1007/s10522-015-9594-8. Epub 2015 Aug 18.
3
Long-term health investment when people underestimate their adaptation to old age-related health problems.
长期健康投资,以防人们低估对老年相关健康问题的适应能力。
Eur J Health Econ. 2013 Dec;14(6):1003-13. doi: 10.1007/s10198-012-0449-9. Epub 2012 Dec 28.
4
Comparing the USA, UK and 17 Western countries' efficiency and effectiveness in reducing mortality.比较美国、英国及17个西方国家在降低死亡率方面的效率和成效。
JRSM Short Rep. 2011 Jul;2(7):60. doi: 10.1258/shorts.2011.011076. Epub 2011 Jul 20.
5
The productivity crisis in pharmaceutical R&D.制药研发的生产力危机。
Nat Rev Drug Discov. 2011 Jun;10(6):428-38. doi: 10.1038/nrd3405.
6
Direct costs of Alzheimer's disease in Germany.德国阿尔茨海默病的直接成本。
Eur J Health Econ. 2011 Dec;12(6):533-9. doi: 10.1007/s10198-010-0267-x. Epub 2010 Jul 18.
7
Trends in risks associated with new drug development: success rates for investigational drugs.新药研发相关风险趋势:研究药物的成功率。
Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3.
8
Comparative effectiveness and health care spending--implications for reform.比较效果与医疗保健支出——对改革的启示
N Engl J Med. 2010 Feb 4;362(5):460-5. doi: 10.1056/NEJMsb0911104. Epub 2010 Jan 6.
9
Spending on new drug development1.新药研发投入
Health Econ. 2010 Feb;19(2):130-41. doi: 10.1002/hec.1454.
10
The return on investment in health care: from 1980 to 2000.医疗保健领域的投资回报率:1980年至2000年
Value Health. 2006 May-Jun;9(3):146-56. doi: 10.1111/j.1524-4733.2006.00095.x.